Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab with nab-paclitaxel and Tegio in advanced gastric/GEJ adenocarcinoma
NCT06241469Phase 2Not yet recruiting
- Start
- Feb 2024
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06241469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06241469.